WallStSmart

Peraso Inc (PRSO)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 2023% more annual revenue ($258.90M vs $12.19M). ZEPP leads profitability with a -15.5% profit margin vs -39.0%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

PRSO

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PRSOUndervalued (+75.2%)

Margin of Safety

+75.2%

Fair Value

$3.50

Current Price

$0.92

$2.58 discount

UndervaluedFair: $3.50Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PRSO2 strengths · Avg: 9.0/10
EPS GrowthGrowth
29139.0%10/10

Earnings expanding 29139.0% YoY

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PRSO4 concerns · Avg: 2.3/10
Market CapQuality
$11.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-117.3%2/10

ROE of -117.3% — below average capital efficiency

Revenue GrowthGrowth
-22.0%2/10

Revenue declined 22.0%

Free Cash FlowQuality
$-1.08M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PRSO

The strongest argument for PRSO centers on EPS Growth, Price/Book.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PRSO

The primary concerns for PRSO are Market Cap, Return on Equity, Revenue Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PRSO profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 34/100) and 43.0% revenue growth. PRSO offers better value entry with a 75.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Peraso Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Peraso, Inc. is primarily engaged in the development and manufacture of 5G mmWave silicon devices. The company is headquartered in San Jose, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?